CyteGen discovers new pathways that impact mitochondrial fitness and demonstrated recovery of cardiovascular and neurological function.
CyteGen has raised $1.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2022.
CyteGen's investors include Breakout Labs.
CyteGen is headquartered in Wauwatosa, United States.
CyteGen discovers new pathways that impact mitochondrial fitness and demonstrated recovery of cardiovascular and neurological function.
CyteGen is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CyteGen — Funding & Investors." VCBacked, January 10, 2022, https://www.vcbacked.co/company/cytegen. Accessed October 1, 2026.
VCBacked. (2022). CyteGen — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/cytegen
{{cite web |title=CyteGen — Funding & Investors |url=https://www.vcbacked.co/company/cytegen |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated